Digital Health Platform Blood Pressure Management Study
NCT ID: NCT07147413
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
10000 participants
INTERVENTIONAL
2025-09-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of a Disease Self-management Program Through a Mobile Applications for Patients With Hypertension
NCT05263726
Self-Management of Blood Pressure in Resistant Hypertension
NCT06819241
An Artificial Intelligence-Assisted Digital Health Lifestyle Intervention for Adults With Hypertension
NCT06337734
The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension
NCT03470974
Effectiveness of Implementation of a Patient-centered Self-management Program in Patients With Hypertensive Nephropathy
NCT04633993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: This two-arm, randomized controlled pilot study enrolled participants aged 18-75 years with hypertension. Participants were allocated to either the AI health education assistant group or the case manager group. The AI group received app-based interventions, including medication reminders, behavioral nudges, educational quizzes, and abnormal blood pressure alerts powered by AI-driven monitoring. The case manager group received personalized lifestyle advice, medication reminders, and regular follow-ups from human case managers. Blood pressure readings were collected at baseline and 6 months, and TAM metrics were assessed through questionnaires. Compliance with health behaviors and engagement in 722 goals were evaluated through app interaction logs. Statistical analyses included paired t-tests for within-group changes, independent t-tests for between-group comparisons, and linear regression models to assess associations between intervention type and TAM metrics, adjusting for baseline values.
Discussion: This study will provide preliminary evidence on the feasibility and potential benefits of AI-driven interventions for hypertension management. It will further evaluate the AI assistant's ability to improve blood pressure control, increase engagement in 722 goals, and enhance technology acceptance. These findings will deliver important insights for clinicians and inform future clinical practice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AI assistant
The AI group received app-based interventions, including medication reminders, behavioral nudges, educational quizzes, and abnormal blood pressure alerts powered by AI-driven monitoring.
Behavioral/Digital Health Intervention
Participants in this group will utilize an AI-powered digital health management platform designed to optimize blood pressure control. The platform provides personalized medication and blood pressure measurement reminders, tailored health education, and interactive quizzes to improve hypertension awareness and engagement. Data from blood pressure monitors will be scanned and uploaded, and the system will alert participants and case managers to abnormal readings, enabling timely interventions.
Case manager
The case manager group received personalized lifestyle advice, medication reminders, and regular follow-ups from human case managers.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Behavioral/Digital Health Intervention
Participants in this group will utilize an AI-powered digital health management platform designed to optimize blood pressure control. The platform provides personalized medication and blood pressure measurement reminders, tailored health education, and interactive quizzes to improve hypertension awareness and engagement. Data from blood pressure monitors will be scanned and uploaded, and the system will alert participants and case managers to abnormal readings, enabling timely interventions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Aged 18 to 75 years at the time of enrollment
2. Able and willing to provide informed consent
3. Able to operate a mobile phone and interact with the digital platform
4. Willing to participate in home blood pressure monitoring
Exclusion Criteria
1. Systolic BP consistently \<120 mmHg and diastolic BP \<70 mmHg, based on baseline home monitoring (considered low BP not targeted in this study)
2. Pregnant or planning to become pregnant during the study period
3. Unable to operate a smartphone or digital device independently
4. Cognitive impairment or language barrier that prevents understanding of study procedures or informed consent
5. Severe comorbidities that may interfere with study participation or outcomes (e.g., advanced heart failure, end-stage renal disease)
6. Current participation in another interventional clinical study that could conflict with this protocol
7. Unwillingness to follow home blood pressure monitoring protocol or adhere to follow-up schedule
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health and Welfare, Taiwan
OTHER_GOV
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-07-021BCF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.